Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPER: Neoadjuvant NORT and Durvalumab for NSCLC
NCT06331455Phase 2Recruiting
- Sponsor
- Marc de Perrot
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Marc de Perrot. Started May 2024; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06331455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06331455.